<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492699</url>
  </required_header>
  <id_info>
    <org_study_id>2010-PTSD-NT/001</org_study_id>
    <nct_id>NCT01492699</nct_id>
  </id_info>
  <brief_title>Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder</brief_title>
  <official_title>Single Site, Open Label Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study for adult subjects with Post Traumatic Stress Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label clinical study to evaluate the efficacy of PRX-03140 in reducing PTSD symptoms
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in adverse events from baseline</measure>
    <time_frame>weekly for 4 weeks then every 4 weeks until week 14</time_frame>
    <description>adverse events will be evaluated at every visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PTSD and mood related symptoms</measure>
    <time_frame>weekly for 4 weeks then every 4 weeks until week 14</time_frame>
    <description>subjects will fill out PTSD and mood related symptoms questionnaires at each visit to show any changes in symptoms from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>PRX-03140</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-03140 for the treatment of PTSD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-03140</intervention_name>
    <description>50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.</description>
    <arm_group_label>PRX-03140</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between ages 18-55

          2. The subject has signed and dated the written informed consent to participate in the
             study

          3. The subject is able to understand and comply with written and verbal protocol
             requirements, instructions, and protocol-stated restrictions

          4. The subject meets criteria for PTSD as defined by the DSM-IV-TR

          5. Stable use of clinically prescribed medications

          6. Subject able to complete baseline, 4 weeks, and 12 week psychological and cognitive
             evaluation

          7. Female subjects - not surgically sterile (hysterectomy, bilateral oophorectomy, or
             bilateral tubal ligation) for at least 6 months or at least 2 years postmenopausal -
             must agree to utilize one of the following forms of contraception, if sexually active
             with a male partner, from screening through completion of the study. Approved forms of
             contraception are abstinence, hormonal (oral, implant, transdermal, vaginal, or
             injection) in use at least 3 consecutive months prior to the first dose of study
             medication, double barrier (condom with spermicide; diaphragm with spermicide),
             intrauterine device (IUD), or vasectomized partner (6 months minimum since vasectomy).

        Exclusion Criteria:

          1. Actively alcohol or drug dependent as defined by DSM-IV-TR Criteria

          2. Patient actively suicidal within last 12-months or with current suicidal ideation

          3. History of schizophrenia, bipolar disorder, attention deficit hyperactivity disorder,
             learning disability, stroke, multiple sclerosis or seizure disorder by interview

          4. Participation in a clinical drug research study within the past 30 days

          5. Subject currently taking any SSRI or anti-depressant medication.

          6. Pregnant or breastfeeding females

          7. Subjects will be excluded based on lab values, ECG findings, or physical findings that
             the Investigators deems exclusionary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Abernethy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ology Bioservices</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Post Traumatic Stress Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 5, 2015</submitted>
    <returned>November 2, 2015</returned>
    <submitted>November 2, 2015</submitted>
    <returned>December 3, 2015</returned>
    <submitted>February 1, 2017</submitted>
    <returned>March 22, 2017</returned>
    <submitted>April 4, 2017</submitted>
    <returned>May 11, 2017</returned>
    <submitted>April 3, 2018</submitted>
    <returned>May 1, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

